Interventional technologies
Offering the broadest portfolio of therapies for peripheral artery disease, venous disease, and cancer uniquely positioned to help you:
- Improve clinical outcomes while reducing cost
- Achieve operational efficiencies
- Increase patient access to care
Bringing innovation in drug-eluting technologies, clot management, and interventional oncology.
- Peripheral artery disease
- Deep vein thrombosis
- Critical limb ischemia
- Pulmonary embolism
- Liver cancer
- Kidney & lung tumors
Evidence-backed drug-eluting portfolio
Eluvia™ Drug-Eluting Stent and RangerTM Drug Coated Balloon are the first devices for peripheral artery disease (PAD) backed by level one randomized controlled trials (RCTs).
Boston Scientific offers two drug-eluting solutions for PAD, both backed by head-to-head trials for comparative effectiveness. Physicians choose the treatment that is right for the lesion and the patient.
Top image: ELUVIA™ Drug-Eluting Stent
Bottom image: Ranger™ Drug-Coated Balloon
4
Randomized-controlled trials (RCTs) between Eluvia and Ranger
With a growing body of clinical evidence demonstrating exceptional outcomes, Boston Scientific is advancing science in the fight against peripheral artery disease.
Eluvia™ drug-eluting vascular stent system
A new standard of care in SFA stenting
No SFA stent has performed better at 2-Years. No matter the lesion complexity. No matter the patient.1,2
| Superior patency | Statistically significant superior primary patency at 1-year over bare metal stents and Zilver™ PTX™ |
| Fewer repeat procedures | Statistically significant reduction in reinterventions at 2 years vs. Zilver™ PTX™5 |
| Shorter hospital stay | 19% reduction (>1 day) in average length of hospital stay vs. Zilver™ PTX™6 |
Ranger™ drug-coated balloon catheter
Exceptional Outcomes. Effortless Deliverability.
Backed by two randomized controlled trials, Ranger DCB consistently demonstrated high primary patency and low reintervention rates.7
Half
The total drug dose8 and similar primary patency as the IN.PACT DCB at 1 & 2-Years9
Lowest
Tip entry profile of any SFA DCB10 for a smooth delivery with excellent trackability
.014"/.018"
Guidewire compatibility can help streamline atherectomy procedures
The most studied and preferred tools for clot management
Boston Scientific is committed to delivering a full suite of interventional tools to target thrombus.
EKOS™ endovascular system
Ultrasound assisted catheter-directed thrombolysis
Dissolves clot with less lytic and short treatment times.
EKOS is clinically proven to be safe and reliable with long-term outcomes. No other device used to treat pulmonary embolism has been studied as much as EKOS. See the evidence.
~90%
Less thrombolytic dose than standard systemic treatment11,12
15 minute procedure that is easy to perform
14
Clinical trials published and >75,000 PE patients treated*
* Data on file
Evidence-based medicine, now backed by updated reimbursement. Reimbursement for the procedure codes applicable to the EKOS system increased October 1, 2020. To help your institution benefit from these changes, access the EKOS coding guide.
AngioJet™ peripheral thrombectomy system
Rapidly removes thrombus via mechanical thrombectomy with optional lytic delivery.
AngioJet is the most studied, most versatile, market-leading thrombectomy platform designed to enable single-session removal of thrombus. The highly effective combination of optional thrombolytic therapy with mechanical thrombectomy may help reduce ICU and total hospital stays due to:
- Faster restoration of flow
- Less lytic
- Shorter treatment time13
AngioJet treats the full range of thrombus:
| Arterial | For acute limb ischemia, AngioJet quickly restores flow and may reduce the need for prolonged lytic therapy and procedure time, leading to a potential cost benefit.14 |
| Venous | Designed specifically to treat deep vein thrombosis, the AngioJet™ ZelanteDVT™ Thrombectomy Catheter paired with ClotHunter™, can increase single-session success and avoid the need for re-intervention. |
| AV access | AngioJet is designed to offer quick removal of thrombotic materials from the dialysis access conduit, potentially improving long-term patency.15 |
Advancing the treatment of cancer and other complex interventional procedures
From the best access and embolization devices to the best therapy devices, Boston Scientific is committed to interventionalists and their patients.
Unrivaled portfolio with targeted treatments
- The largest Interventional Oncology (IO) and Embolization portfolio with a robust pipeline
- TheraSphere™ - the only Y-90 therapy approved for hepatocellular carcinoma
- EmboldTM Fibered Coil, a fully retractable, .018”, highly thrombogenic15 coil built to maximize procedural flexibility and reliability
Leading-edge clinical research
- ~$60M per year in R&D and clinical investments specific to IO and Embolization
- 14 trials for expanded indications to treat more disease states
- 3,000 patients enrolled in clinical studies and registries16
Advancing the specialty
- 5,000+ physicians and techs trained and educated17,18
- 50 global investigator-initiated studies with support from Boston Scientific
- Therapy awareness and education programs for Interventionalists and beyond
Peripheral Interventions resources
Coding and payment guides
References:
1. Highest-two year primary patency based on 24-month Kaplan-Meier estimates reported for IMPERIAL, IN.PACT SFA, ILLUMENATE, LEVANT II and Primary Randomization for ZilverPTX RCT. Intention to treat. Kaplan-Meier estimate utilizing time-to-event of clinically-driven TLR up to 730 days and Duplex Ultrasound data at 24 months. Primary patency defined as duplex ultrasound PSVR ≤2.4, in the absence of clinically-driven target lesion revascularization or bypass of the target lesion, as assessed by the DUS core lab
2. In IMPERIAL RCT, Eluvia K-M Primary Patency was 83% vs. 77.1% for ZilverPTX at 24 months, p=0.1008. Diabetic Subgroup Analysis = Medically Treated Diabetes
3. EMINENT Trial: A global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against commercially-available Self-Expanding Bare Nitinol Stents, single-blind, superiority design; independent core lab adjudication. 12-Month Primary Patency rate of 83.2% in the Eluvia arm vs. 74.3% in the Bare-Metal Stenting arm (p-value = 0.0077)
4. IMPERIAL Trial: A global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against Cook Medical’s Zilver™ PTX™ Stent, single-blind, non-inferiority design; independent core lab adjudication. Superiority determined in a post hoc analysis that was specified prior to unblinding. 12-Month Primary Patency rate of 86.8% in the Eluvia arm vs. 77.5% in the ZilverPTX arm (p-value = 0.0144)
5. IMPERIAL RCT 2-Year ITT Clinically-Driven TLR data (Eluvia 12.7% vs. Zilver PTX 20.1%, p=0.0495)
6. Boston Scientific’s ELUVIA Drug-Eluting Stent and Coronary Paclitaxel-Eluting Stent Clinical Experience. Available at: https://www.fda.gov/media/128145/download [Accessed July 4 2019]Kbr/> Gray WA et al. Lancet. 2018 Oct 27;392(10157):1541-1551; 2-Year Results from IMPERIAL Trial; Presented at LINC 2020
7. COMPARE Clinical Trial 1-Year Results presented by Sabine Steiner, MD. LINC 2020. K-M Primary Patency = 88.4%. RANGER II SFA Pivotal Trial 1-Year Results presented by Marianne Brodmann. LINC 2020. K-M Primary Patency = 89.8%
8. Based on total drug dose for (4mmx60mm) or (averages for full size matrix) per the Ranger and IN.PACT DCB Directions for Use
9. COMPARE Head-to-Head RCT 2-Year Results presented by Sabine Steiner, MD. LINC 2021
10. Boston Scientific Data on File. Ranger Catheter Competitive Testing Report, 92517674. Measurements taken from 6 x 120 devices for Ranger DCB, Lutonix™ 035 DCB, IN.PACT Admiral DCB and Stellarex™ 035 DCB. Lutonix 018 DCB measurements taken from 6 x 150 devices
11. Tapson V et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism. JACC: Cardiovascular Interventions 2018; 11(14):1401-1410
12. Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347:1143–1150
13. The PEARL Registry study
14. Presented by Dr. Ali Amin at Charing Cross 2014; Final PEARL Data Aug 2013
15. Only Thrombogenicity in a pre-clinical model: testing results from bovine blood flow loop. Occlusion time is an average of a single 6 x 20 coil from each manufacturer performed three times. Bench Test or pre-clinical study results may not necessarily be indicative of clinical performance
16. Presented by Dr. Eugene Simoni at VEITH 2013; Final PEARL Data Aug 2013 Simoni. PEARL Registry Hemodialysis Access. VEITH 2013
17. Patients enrolled in ongoing company-sponsored prospective clinical trials, registries, and ISRs
18. Includes in-person and virtual educational programs 2020-2021